Hamada Taku, Kotani Kazuhiko, Tsuzaki Kokoro, Sano Yoshiko, Murata Takashi, Tabata Masahiko, Sato Shigeaki, Sakane Naoki
Department of Preventive Medicine and Diabetes Education, Clinical Research Institute for Endocrinology and Metabolic Disease, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan.
Metabolism. 2007 Oct;56(10):1345-9. doi: 10.1016/j.metabol.2007.05.017.
The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma2 (PPARgamma2) gene has been reported to predict a lower risk for developing type 2 diabetes mellitus. However, its effect on the lipid profile has been disputable. Among low-density lipoproteins, small dense low-density lipoprotein (sdLDL) particles have been linked to a greater risk for coronary artery disease. The purpose of this study was to investigate the genetic effect of the Pro12Ala polymorphism in the PPARgamma2 gene on the presence of sdLDL in the general Japanese population. In 379 subjects (aged 54 +/- 13 years), body mass index, percentage of body fat, blood pressure, and biochemical profiles were measured. Pro12Ala polymorphism was genotyped by polymerase chain reaction-restriction fragment length polymorphism. The area of sdLDL subfractions (sdLDL4-7) was analyzed by high-resolution polyacrylamide gel electrophoresis. The frequency of the Ala12 allele in PPARgamma2 was 0.04. There was no difference in total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels between genotypes. However, subjects with the X/Ala genotype (Pro/Ala + Ala/Ala) had significantly higher serum triglyceride levels (P = .001) and a larger area of sdLDL4-7 (P = .002) than those with the Pro/Pro genotype. Multiple regression analysis revealed that the Ala12 allele was a significant variable contributing to the variance in the increased area of sdLDL4-7 (P = .040). In conclusion, the Pro12Ala polymorphism in the PPARgamma2 gene was positively associated with an enlarged area of sdLDL4-7. This polymorphism may play a role in the genetic predisposition to increases in sdLDL4-7.
据报道,过氧化物酶体增殖物激活受体γ2(PPARγ2)基因的Pro12Ala多态性预示着患2型糖尿病的风险较低。然而,其对血脂谱的影响一直存在争议。在低密度脂蛋白中,小而密的低密度脂蛋白(sdLDL)颗粒与冠状动脉疾病风险增加有关。本研究的目的是调查PPARγ2基因Pro12Ala多态性对日本普通人群中sdLDL存在情况的遗传效应。对379名受试者(年龄54±13岁)测量了体重指数、体脂百分比、血压和生化指标。采用聚合酶链反应-限制性片段长度多态性方法对Pro12Ala多态性进行基因分型。通过高分辨率聚丙烯酰胺凝胶电泳分析sdLDL亚组分(sdLDL4-7)的面积。PPARγ2中Ala12等位基因的频率为0.04。不同基因型之间的总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平没有差异。然而,X/Ala基因型(Pro/Ala+Ala/Ala)的受试者血清甘油三酯水平显著更高(P=0.001),sdLDL4-7面积更大(P=0.002),高于Pro/Pro基因型的受试者。多元回归分析显示,Ala12等位基因是导致sdLDL4-7面积增加变异的一个显著变量(P=0.040)。总之,PPARγ2基因的Pro12Ala多态性与sdLDL4-7面积增大呈正相关。这种多态性可能在sdLDL4-7增加的遗传易感性中起作用。
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002-6
Exp Clin Endocrinol Diabetes. 2009-11